Mukul Vasant Patharkar, MD | |
1265 Highway 54 W, Suite 500-c, Fayetteville, GA 30214-4548 | |
(678) 435-3040 | |
(678) 435-3044 |
Full Name | Mukul Vasant Patharkar |
---|---|
Gender | Male |
Speciality | Infectious Disease |
Experience | 21 Years |
Location | 1265 Highway 54 W, Fayetteville, Georgia |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1922157338 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207RI0200X | Internal Medicine - Infectious Disease | 73781 (Georgia) | Primary |
207RI0200X | Internal Medicine - Infectious Disease | 073781 (Georgia) | Secondary |
Facility Name | Location | Facility Type |
---|---|---|
Central Home Health Care, An Amedisys Company | Douglasville, GA | Home health agency |
Piedmont Fayette Hospital | Fayetteville, GA | Hospital |
Piedmont Newnan Hospital, Inc | Newnan, GA | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Atlanta Id Group Pc | 9638120231 | 12 |
News Archive
Researchers at Moffitt Cancer Center have completed a phase II clinical trial to determine the safety and efficacy of dasatinib for patients with higher-risk myelodysplastic syndromes, chronic myelomonocytic leukemia, or acute myeloid leukemia resulting from MDS and have failed treatment with azanucleosides.
Doug Harrison, CEO and Founder of The SCOOTER Store, is outraged that misleading data from a U.S. Department of Health and Human Services (HHS) Inspector General's report was recently cited during a Fox News Channel segment on the costs of providing medical equipment to Medicare beneficiaries.
Researchers from the Icahn School of Medicine at Mount Sinai found an elevated risk of major congenital malformations in fetuses after first-trimester exposure to lithium, in the largest study ever to examine the risk of birth defects in lithium-exposed babies.
Young children suffering from diarrheal diseases are less likely to receive life-saving oral rehydration therapy (ORT) if they seek treatment at private, for-profit clinics, according to the first-ever, large-scale study of child diarrhea treatment practices in sub-Saharan Africa.
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), today announced that the United States Patent and Trademark Office (PTO) has issued United States Patent Number 7,569,551 entitled "Chemo-and Radiation-sensitization of Cancer by Antisense TRPM-2 Oligodeoxynucleotides," on the method of using OncoGenex' lead cancer drug candidate, OGX-011, to treat certain cancers.
› Verified 5 days ago
Entity Name | Atlanta Id Group Pc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1699805697 PECOS PAC ID: 9638120231 Enrollment ID: O20101227000096 |
News Archive
Researchers at Moffitt Cancer Center have completed a phase II clinical trial to determine the safety and efficacy of dasatinib for patients with higher-risk myelodysplastic syndromes, chronic myelomonocytic leukemia, or acute myeloid leukemia resulting from MDS and have failed treatment with azanucleosides.
Doug Harrison, CEO and Founder of The SCOOTER Store, is outraged that misleading data from a U.S. Department of Health and Human Services (HHS) Inspector General's report was recently cited during a Fox News Channel segment on the costs of providing medical equipment to Medicare beneficiaries.
Researchers from the Icahn School of Medicine at Mount Sinai found an elevated risk of major congenital malformations in fetuses after first-trimester exposure to lithium, in the largest study ever to examine the risk of birth defects in lithium-exposed babies.
Young children suffering from diarrheal diseases are less likely to receive life-saving oral rehydration therapy (ORT) if they seek treatment at private, for-profit clinics, according to the first-ever, large-scale study of child diarrhea treatment practices in sub-Saharan Africa.
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), today announced that the United States Patent and Trademark Office (PTO) has issued United States Patent Number 7,569,551 entitled "Chemo-and Radiation-sensitization of Cancer by Antisense TRPM-2 Oligodeoxynucleotides," on the method of using OncoGenex' lead cancer drug candidate, OGX-011, to treat certain cancers.
› Verified 5 days ago
Mailing Address | Practice Location Address |
---|---|
Mukul Vasant Patharkar, MD 77 12th St Ne, Apt 2012, Atlanta, GA 30309-3972 Ph: (347) 247-9526 | Mukul Vasant Patharkar, MD 1265 Highway 54 W, Suite 500-c, Fayetteville, GA 30214-4548 Ph: (678) 435-3040 |
News Archive
Researchers at Moffitt Cancer Center have completed a phase II clinical trial to determine the safety and efficacy of dasatinib for patients with higher-risk myelodysplastic syndromes, chronic myelomonocytic leukemia, or acute myeloid leukemia resulting from MDS and have failed treatment with azanucleosides.
Doug Harrison, CEO and Founder of The SCOOTER Store, is outraged that misleading data from a U.S. Department of Health and Human Services (HHS) Inspector General's report was recently cited during a Fox News Channel segment on the costs of providing medical equipment to Medicare beneficiaries.
Researchers from the Icahn School of Medicine at Mount Sinai found an elevated risk of major congenital malformations in fetuses after first-trimester exposure to lithium, in the largest study ever to examine the risk of birth defects in lithium-exposed babies.
Young children suffering from diarrheal diseases are less likely to receive life-saving oral rehydration therapy (ORT) if they seek treatment at private, for-profit clinics, according to the first-ever, large-scale study of child diarrhea treatment practices in sub-Saharan Africa.
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), today announced that the United States Patent and Trademark Office (PTO) has issued United States Patent Number 7,569,551 entitled "Chemo-and Radiation-sensitization of Cancer by Antisense TRPM-2 Oligodeoxynucleotides," on the method of using OncoGenex' lead cancer drug candidate, OGX-011, to treat certain cancers.
› Verified 5 days ago
Carzadean Bernadette Hall, M.D. Infectious Disease Medicare: Not Enrolled in Medicare Practice Location: 185 Franklin Farms Cir, Fayetteville, GA 30214 Phone: 404-216-0132 | |
Vipin Ramprasad Lohiya, M.D. Infectious Disease Medicare: May Accept Medicare Assignments Practice Location: 1267 Highway 54 W Ste 4200, Fayetteville, GA 30214 Phone: 678-829-1060 Fax: 678-829-1099 | |
Connie Dupre, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 1267 Highway 54 W, Suite 5200, Fayetteville, GA 30214 Phone: 770-719-5601 | |
Sushee C Gadde, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 1267 Highway 54 W Ste 2200, Fayetteville, GA 30214 Phone: 770-716-0051 Fax: 770-716-0087 | |
Dr. John E Burney, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 1265 Highway 54 W, Ste 402, Fayetteville, GA 30214 Phone: 678-817-6550 Fax: 404-350-8795 | |
Dr. Bryan L Woods, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 1265 Highway 54 W, Ste 402, Fayetteville, GA 30214 Phone: 770-719-3240 Fax: 770-719-3241 | |
Dr. Arvind Jayaraj Ponnambalam, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 1255 Highway 54 W, Fayetteville, GA 30214 Phone: 404-367-3014 |